KSCM
VRTX icon

Kamunting Street Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Kamunting Street Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,500
Closed -$2.52M – 80
2021
Q2 		$2.52M Buy
+12,500
New +$2.61M 1.02% 32

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kamunting Street Capital Management's VRTX Position: Q2 2021 in Review

Kamunting Street Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 4,000 shares — an estimated $837K sold.

Kamunting Street Capital Management first reported a position in VRTX in Q1 2021 and held it in 1 quarter. The position peaked at $860K in Q1 2021. 977 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

  • Kamunting Street Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Kamunting Street Capital Management sold 4,000 Vertex Pharmaceuticals shares in Q2 2021, an estimated $837K.
  • Kamunting Street Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Kamunting Street Capital Management's Vertex Pharmaceuticals position peaked at $860K in Q1 2021.
  • 977 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Kamunting Street Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.